Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,186 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of vascular patients at very high risk for recurrent cardiovascular events: validation of the current ACC/AHA very high risk criteria.
van den Berg MJ, Bhatt DL, Kappelle LJ, de Borst GJ, Cramer MJ, van der Graaf Y, Steg PG, Visseren FLJ; SMART study group; REACH Registry investigators. van den Berg MJ, et al. Among authors: steg pg. Eur Heart J. 2017 Nov 14;38(43):3211-3218. doi: 10.1093/eurheartj/ehx102. Eur Heart J. 2017. PMID: 28369481
A global view of atherothrombosis: baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial.
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, Cacoub P, Cohen EA, Creager MA, Easton JD, Flather MD, Haffner SM, Hamm CW, Hankey GJ, Johnston SC, Mak KH, Mas JL, Montalescot G, Pearson TA, Steg PG, Steinhubl SR, Weber MA, Booth J, Topol EJ; CHARISMA Investigators. Bhatt DL, et al. Among authors: steg pg. Am Heart J. 2005 Sep;150(3):401. doi: 10.1016/j.ahj.2005.03.017. Am Heart J. 2005. PMID: 16169314 Clinical Trial.
The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events-study design.
Ohman EM, Bhatt DL, Steg PG, Goto S, Hirsch AT, Liau CS, Mas JL, Richard AJ, Röther J, Wilson PW; REACH Registry Investigators. Ohman EM, et al. Among authors: steg pg. Am Heart J. 2006 Apr;151(4):786.e1-10. doi: 10.1016/j.ahj.2005.11.004. Am Heart J. 2006. PMID: 16569533
Impact of carotid endarterectomy on medical secondary prevention after a stroke or a transient ischemic attack: results from the Reduction of Atherothrombosis for Continued Health (REACH) registry.
Touzé E, Mas JL, Röther J, Goto S, Hirsch AT, Ikeda Y, Liau CS, Ohman EM, Richard AJ, Wilson PW, Steg PG, Bhatt DL; REACH Registry Investigators. Touzé E, et al. Among authors: steg pg. Stroke. 2006 Dec;37(12):2880-5. doi: 10.1161/01.STR.0000249411.44097.5b. Epub 2006 Oct 26. Stroke. 2006. PMID: 17068303
Comparisons of guideline-recommended therapies in patients with documented coronary artery disease having percutaneous coronary intervention versus coronary artery bypass grafting versus medical therapy only (from the REACH International Registry).
Steinberg BA, Steg PG, Bhatt DL, Fonarow GC, Zeymer U, Cannon CP; REACH Registry Investigators. Steinberg BA, et al. Among authors: steg pg. Am J Cardiol. 2007 May 1;99(9):1212-5. doi: 10.1016/j.amjcard.2006.12.039. Epub 2007 Mar 16. Am J Cardiol. 2007. PMID: 17478144
An analysis of mortality rates with dual-antiplatelet therapy in the primary prevention population of the CHARISMA trial.
Wang TH, Bhatt DL, Fox KA, Steinhubl SR, Brennan DM, Hacke W, Mak KH, Pearson TA, Boden WE, Steg PG, Flather MD, Montalescot G, Topol EJ; CHARISMA Investigators. Wang TH, et al. Among authors: steg pg. Eur Heart J. 2007 Sep;28(18):2200-7. doi: 10.1093/eurheartj/ehm274. Epub 2007 Aug 2. Eur Heart J. 2007. PMID: 17673448 Clinical Trial.
Risk factor profile and management of cerebrovascular patients in the REACH Registry.
Röther J, Alberts MJ, Touzé E, Mas JL, Hill MD, Michel P, Bhatt DL, Aichner FT, Goto S, Matsumoto M, Ohman EM, Okada Y, Uchiyama S, D'Agostino R, Hirsch AT, Wilson PW, Steg PG; REACH Registry Investigators. Röther J, et al. Among authors: steg pg. Cerebrovasc Dis. 2008;25(4):366-74. doi: 10.1159/000120687. Epub 2008 Mar 13. Cerebrovasc Dis. 2008. PMID: 18337635
Incomplete inhibition of thromboxane biosynthesis by acetylsalicylic acid: determinants and effect on cardiovascular risk.
Eikelboom JW, Hankey GJ, Thom J, Bhatt DL, Steg PG, Montalescot G, Johnston SC, Steinhubl SR, Mak KH, Easton JD, Hamm C, Hu T, Fox KA, Topol EJ; Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) Investigators. Eikelboom JW, et al. Among authors: steg pg. Circulation. 2008 Oct 21;118(17):1705-12. doi: 10.1161/CIRCULATIONAHA.108.768283. Epub 2008 Oct 6. Circulation. 2008. PMID: 18838564 Clinical Trial.
1,186 results